Selected article for: "loss function and lung disease"
Author: Wu, Huajie; Li, Yan; Wang, Yanxia; Xu, Dunquan; Li, Congcong; Liu, Manling; Sun, Xin; Li, Zhichao
Title: Tanshinone IIA Attenuates Bleomycin-Induced Pulmonary Fibrosis via Modulating Angiotensin-Converting Enzyme 2/ Angiotensin-(1-7) Axis in Rats
  • Document date: 2014_4_7
    • ID: td2uk2wc_1
    Snippet: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease which is characterized by rapidly progressive scarring of the lung tissue, together with exacerbated fibroblast proliferation, excessive accumulation of matrix proteins, and destruction of alveolar structure [1, 2] . All those changes will grad-ually result in loss of lung function and, ultimately, respiratory failure. IPF is an age-related disease with a poor prognosis, and.....
    Document: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease which is characterized by rapidly progressive scarring of the lung tissue, together with exacerbated fibroblast proliferation, excessive accumulation of matrix proteins, and destruction of alveolar structure [1, 2] . All those changes will grad-ually result in loss of lung function and, ultimately, respiratory failure. IPF is an age-related disease with a poor prognosis, and the median survival of IPF patients from disease diagnosis to death is usually no more than 3 years [2] . The exact etiology of IPF is still unclear and there are limited proven treatment op-Ivyspring International Publisher tions. Current therapies such as anti-inflammatory, immunosuppressive, or anti-fibrotic methods showed no promising results to halt the progression of the disease or to improve the quality of life [3] . Therefore, it is urgent to further investigate the pathophysiological mechanisms and explore novel therapeutic strategies for treating PF.

    Search related documents:
    Co phrase search for related documents
    • alveolar structure and idiopathic pulmonary fibrosis: 1, 2
    • alveolar structure and IPF idiopathic pulmonary fibrosis: 1, 2
    • current therapy and disease diagnosis: 1, 2, 3, 4, 5, 6, 7
    • current therapy and disease progression: 1, 2, 3, 4, 5, 6, 7
    • current therapy and disease progression halt: 1
    • death disease diagnosis and disease diagnosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • death disease diagnosis and disease progression: 1
    • disease diagnosis and fibroblast proliferation: 1
    • disease diagnosis and idiopathic pulmonary fibrosis: 1, 2, 3, 4, 5, 6
    • disease diagnosis and IPF idiopathic pulmonary fibrosis: 1, 2
    • disease diagnosis and IPF patient: 1
    • disease progression and idiopathic pulmonary fibrosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • disease progression and IPF idiopathic pulmonary fibrosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • disease progression and IPF patient: 1
    • excessive accumulation and idiopathic pulmonary fibrosis: 1, 2, 3
    • excessive accumulation and IPF idiopathic pulmonary fibrosis: 1, 2
    • fibroblast proliferation and idiopathic pulmonary fibrosis: 1, 2, 3, 4, 5
    • fibroblast proliferation and IPF idiopathic pulmonary fibrosis: 1, 2, 3, 4, 5
    • idiopathic pulmonary fibrosis and IPF patient: 1, 2, 3, 4, 5, 6, 7, 8, 9